A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Summary

The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.

Timeline

Start

2017-04-26

Primary completion

2018-05-03

Completion

2018-05-03

Outcome

Outcome not reported

Stopped (Business): “The decision to discontinue the study was based on business reasons.”

Drugs

Indications